Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies
Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn